Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma

Publication date: April 2017
Source:Hematology/Oncology Clinics of North America, Volume 31, Issue 2
Author(s): Enrica Marchi, Alexander G. Raufi, Owen A. O'Connor

Teaser

Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of mature T-cell malignancies associated with exceptionally poor prognoses. Currently, chemotherapy remains the standard of care, but outcomes are suboptimal, with 5-year survival rates ranging from 15% to 25%. In recent years, several novel agents, including pralatrexate, romidepsin, belinostat, and brentuximab vedotin, have been approved for the treatment of relapsed/refractory PTCL. In addition, numerous other therapies with different mechanisms of action and targets are currently under investigation. This article discusses in detail agents currently available, those currently under investigation, and active combination trials.


http://ift.tt/2oEcjCP